ArticleNature cancer2021
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 119 citations in OpenAlex.
- Glutamine-driven metabolic reprogramming promotes CAR-T cell function through mTOR-SREBP2 mediated HMGCS1 upregulation in ovarian cancer.Journal of translational medicine · 2025Trial
- Metabolic vulnerabilities in ovarian cancer decoding the nexus between nutrient adaptation and therapy resistance.Journal of advanced research · 2026Review
- Unraveling the role of glutamine metabolism in cancer: from cell death mechanisms to tumor microenvironment modulation.Experimental hematology & oncology · 2026Review
- Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers · 2026Review
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- Novel Exploratory Transcriptomic Candidates as Biomarkers and Cancer Hallmark Fingerprints for Ovarian Endometroid and Clear Cell Carcinomas in Women.Antioxidants (Basel, Switzerland) · 2026Article
- Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications.Journal of hematology & oncology · 2026Review
- GLS1 Orchestrates Exosome-Mediated Tumor-Endothelial Communication to Facilitate Angiogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- From Pathway Tracing to Actionable Targets: Integrative Mendelian Randomization and Experimental Triangulation Map Metabolic Pathways Across Ovarian Cancer Histotypes.International journal of molecular sciences · 2026Article
- Overview of glutamine metabolism in stromal components of the tumor microenvironment and potential anti-tumor therapies.Genes & diseases · 2026Review
- ARID1A deficiency-driven reprogramming of polyamine metabolism promotes endometrial cancer malignancy and immune escape.Cell death & disease · 2026Article
- The SWI/SNF complex in tumor metabolism: Mechanisms and therapeutic implications.The Journal of biological chemistry · 2026Review
- Metabolic reprogramming in cancer: dysregulation of glucose, lipid, and amino acid pathways and therapeutic opportunities.Molecular biomedicine · 2026Review
- Metabolomic and transcriptomic analyses identify metabolic alterations and immune suppression in ovarian cancer.Scientific reports · 2026Article
- Inhibition of glutamine metabolism blocks tumor growth and sensitizes ccRCC to immune checkpoint blockade.Journal of translational medicine · 2026Article
- Mechanical regulation of metabolism, epigenetics, and their interplay.npj biomedical innovations · 2026Review
- Glutamine Metabolism: Role in Cancer Cell Proliferation and Survival.Cancer treatment and research · 2026Review
- NUFIP1 gain of function promotes fibrotic remodeling and reveals a ZNHIT3-linked metabolic vulnerability in idiopathic pulmonary fibrosis models.Frontiers in immunology · 2026Article
- Amino acids metabolism: a potential target for cancer treatment.Molecular cancer · 2025Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Shuai WuImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-3183-5081
Takeshi FukumotoImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Jianhuang LinImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-0035-0938
Timothy NacarelliImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Yemin WangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Dionzie OngDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Heng LiuImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Nail FatkhutdinovImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-3152-9321
Joseph A ZundellImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Sergey KarakashevImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Wei ZhouImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Lauren E SchwartzDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Hsin-Yao TangProteomics and Metabolomics Facility, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-1838-018X
Ronny DrapkinDepartment of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-6912-6977
Qin LiuMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9964-580X
David G HuntsmanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Andrew V KossenkovImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
David W SpeicherProteomics and Metabolomics Facility, The Wistar Institute, Philadelphia, PA, USA.
Zachary T SchugMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
Chi Van DangMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
Rugang ZhangImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA. rzhang@wistar.org.ORCID http://orcid.org/0000-0002-7255-2360
The Wistar Institute · USUniversity of British Columbia · CACancer Research Center · USUniversity of Pennsylvania · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MSTRUCTURAL BASIS FOR EPIGENETICS IN AGING AND LONGEVITYP01AG031862 · NIA · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2008 to 2022
$28.3MSPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Tian-Li Wang · 2018 to 2026
$20.5MMechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancerR01CA202919 · NCI · WISTAR INSTITUTE · PI Xi Chen, Rugang Zhang · 2016 to 2026
$4.1MRole of BRCA1 Pathway in Regulating Oncogene-Induced SenescenceR01CA160331 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2012 to 2021
$4.0MTargeting EZH2 in CARM1-expressing epithelial ovarian cancerR01CA163377 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2012 to 2021
$3.7MThe Tumor Suppressor Role of SMARCA4 in SCCOHTR01CA195670 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUNTSMAN, DAVID, TRENT, JEFFREY M. · 2015 to 2019
$3.7MThe multifaceted role of acetate in cancerDP2CA249950 · NCI · WISTAR INSTITUTE · PI SCHUG, ZACHARY T · 2019 to 2019
$2.7MSynthetic lethality based combination approaches to ARID1A mutation in ovarian cancerR01CA239128 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2019 to 2024
$2.5MAdvancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1MIntegrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelR50CA211199 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2016 to 2026
$1.6MNCI NIH HHS DP2 CA249950NCI NIH HHS F31 CA247336NCI NIH HHS K99 CA241395NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA228991NCI NIH HHS R00 CA241395NCI NIH HHS R01 CA160331NCI NIH HHS R01 CA163377NCI NIH HHS R01 CA195670NCI NIH HHS R01 CA202919NCI NIH HHS R01 CA239128NCI NIH HHS R50 CA211199NCI NIH HHS R50 CA221838NIA NIH HHS P01 AG031862NIH HHS S10 OD023586NIH HHS S10 OD023658
Abstract
Alterations in components of the SWI/SNF chromatin-remodeling complex occur in ~20% of all human cancers. For example,
Indexed as
Adenocarcinoma, Clear CellOvarian NeoplasmsAnimalsDNA-Binding ProteinsFemaleGlutaminaseGlutamineHumansImmune Checkpoint InhibitorsMiceNuclear ProteinsTranscription FactorsARID1A protein, humanArid1a protein, mouseDNA-Binding ProteinsGLS1 protein, mouseGlutaminaseGlutamineImmune Checkpoint InhibitorsNuclear ProteinsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.